참고문헌
- Whittington JE, Holland AJ, Webb T, Butler JV, Clarke DJ, Boer H. Population prevalence and estimated birth incidence and mortality rate for peple with Prader-Willi Syndrome in on UK Health Region. J Med Genet 2001;38:792-8. https://doi.org/10.1136/jmg.38.11.792
- Scerif M, Goldstone AP, Korbonits M. Ghrelin in obeisty and endocrine diseases. Mol cell Endocrinol 2011;96:E225-32.
- Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, Kangawa K, et al. Endogenous ghrelin in pancratic islets resticts insulin release by attenuating Ca2+ signaling in betacells: implication in the glycemic control in redents. Diabetes 2004;53:3142-51. https://doi.org/10.2337/diabetes.53.12.3142
- Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, et al. Visceral adipose tissue and metabolic complications of oesity are reduced in Prader-Willi syndrome female aduls: evidence for novel influences on body fat distribution. J Clin Endocinol Metab 2001;86:4330-8. https://doi.org/10.1210/jcem.86.9.7814
- Talebizadeh Z, Butler MG. Insulin resistance and obesityreleated factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet 2005;67:230-9.
- Lacroix D, Moutel S, Coupaye M, Huvenne H, Faucher P, Pelloux V, et al. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab 2015;100:850-9. https://doi.org/10.1210/jc.2014-3127
- Purtell L, Viardot A, Sze L, Loughnan G, Steinbeck K, Sainsbury A, et al. Postprandial metabolism in adults with Prader-Willi syndrome. Obesity (silver Spring) 2015;23:1159-65. https://doi.org/10.1002/oby.21041
- Berthoud HR, Powley TL. Morphology and distribution of efferent vagal innervation of rat pancreas as revealed with anterograde transport of Dil. Brain Res 1991;553:336-41. https://doi.org/10.1016/0006-8993(91)90846-N
- Irizarry KA, Miller M, Freemark M, Haqq AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr 2016;63:47-77. https://doi.org/10.1016/j.yapd.2016.04.005
- Butler JV, Whittington JE, Holland AJ, Boer H, Clarke C, Webb T. Prevalence of, and risk factors for, physical illhealth in people with Prader-Willi syndrome: a populationbased study. Dev Med Child Neurol 2002;44:248-55. https://doi.org/10.1017/S001216220100202X
- Laurier V, Lapeyrade A, Copet P, Demeer G, Silvie M, Bieth E, et al. Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France. J Intellect Disabil Res 2015;59:411-21. https://doi.org/10.1111/jir.12140
- Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome-data from 142 children of the French database. Horm Res Paediatr 2010;74:121-8. https://doi.org/10.1159/000313377
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42. https://doi.org/10.1038/nrendo.2012.140
- Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrionl Metab 2011;96:E1314-9. https://doi.org/10.1210/jc.2011-0038
- Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crino A. Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases. Diabetes Care 2014;37:e76-7. https://doi.org/10.2337/dc13-2575
피인용 문헌
- Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome vol.33, pp.7, 2016, https://doi.org/10.1111/jne.12994